<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
  <title>
  </title>
  <meta content="width=device-width, initial-scale=1.0" name="viewport"/>
 </head>
 <body style="margin: 0; padding: 0;">
  <table border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
    <td style="padding: 10px 0 30px 0;">
     <table align="center" border="0" cellpadding="0" cellspacing="0" style="border: 1px solid #cccccc; border-collapse: collapse;" width="600">
      <tr>
       <td align="center" bgcolor="#ffffff" style="padding: 10px 0px 0px 0px">
        <a href="https://academic.oup.com/abt">
         <!----------------------------------------------------------------------------------
                             header image source. If image is hosted on github repo, add `?raw=True` after url
                            ----------------------------------------------------------------------------------->
         <img alt="Logo" src="https://res.cloudinary.com/dwawcx2hl/image/upload/v1589410052/Headers/new_article_alert_header_iyr9ub.png" width="100%"/>
        </a>
       </td>
      </tr>
      <tr>
       <td bgcolor="#ffffff" style="padding: 30px 30px 40px 30px;">
        <table border="0" cellpadding="0" cellspacing="0" width="100%">
         <tr>
          <td align="center" bgcolor="#E5E7E9" style="color: black; font-family: Verdana, sans-serif; padding: 6px 0px 6px 0px ">
           <!-----------------------------------------------------------------
                                                            Date
                                    ----------------------------------------------------------------->
           <b id="date">
            July 21, 2020
           </b>
          </td>
         </tr>
         <tr>
          <td id="title" style="color: #43729F; font-family: Verdana, sans-serif; font-size: 26px; padding: 30px 10px 30px 10px ">
           Perspectives on the development of neutralizing antibodies against SARS-CoV-2
          </td>
         </tr>
         <tr>
          <td bgcolor="43729f" style="color:white; font-family: Verdana, sans-serif; font-size: 20px;padding: 10px 15px 10px 15px">
           Editor's Note
          </td>
         </tr>
         <tr>
          <td bgcolor="d4f5ff" id="editor_notes" style="color:#5c5c5c; font-family: Geneva, sans-serif; font-size: 16px;padding: 30px 15px 30px 15px">
           We are pleased to introduce a recent article published in Antibody Therapeutics, an official journal of Chinese Antibody Society, entitled “Perspectives on the development of neutralizing antibodies against SARS-CoV-2”. The author is Dr. Mitchell Ho, Senior Investigator at National Cancer Institute, NIH, USA. It is the 3rd COVID-19 related articles published in Antibody Therapeutics through the fast track review process which took only 13 days from submission to online publication. The following is the abstract of this review article.
          </td>
         </tr>
         <tr>
          <td align="center" style="padding: 30px 10px 2px 10px ">
           <!----------------------------------------------------------------------------------------------------------------
                                    Article Image (Depending on actual image, it might require slight adjustment of width/height to prevent distortion
                                    ------------------------------------------------------------------------------------------------------------------>
           <img alt="article" src="https://res.cloudinary.com/dwawcx2hl/image/upload/v1590424613/Newsletter/5-25-20_l2rfzd.png" style="display: block;" width="100%">
           </img>
          </td>
         </tr>
         <tr>
          <td align="center" style="padding: 0px 0px 20px 0px; color: #5c5c5c; font-family: Geneva, sans-serif; font-size: 16px;">
           <hr width="640"/>
           <!-----------------------------------------------------------------
                                                           Figure Caption
                                     ----------------------------------------------------------------->
           <p id="figure_caption">
            Figure 1. Development of neutralizing antibodies for treating COVID-19.
           </p>
           <!-----------------------------------------------------------------
                                                           Url to Article
                                    ----------------------------------------------------------------->
           <p>
            <a href="https://academic.oup.com/abt/advance-article/doi/10.1093/abt/tbaa009/5841095" id="url">
             Free access to full article
            </a>
           </p>
          </td>
         </tr>
         <tr>
          <td id="main_text" style="padding: 10px 0 30px 0; color: #5c5c5c; font-family: Geneva, sans-serif; font-size: 16px; line-height: 20px;">
           <p>SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein is the primary target for neutralizing antibodies. Selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV are attractive and might be useful for treating not only COVID-19, but also future SARS-related CoV infections. Broad-neutralizing antibodies, such as 47D11, S309, and VHH-72, have been reported to target a conserved region in the RBD of the S1 subunit. The S2 subunit required for viral membrane fusion might be another target. Due to their small size and high stability, single-domain antibodies might have the ability to be administered by an inhaler making them potentially attractive therapeutics for respiratory infections. A cocktail strategy combining two (or more) antibodies that recognize different parts of the viral surface that interact with human cells might be the most effective (see the Figure 1)</p> <p>You are welcome to read the full length of this article (currently uncorrected manuscript free of charge by clicking on link above. You are also welcome to cite this article in your own manuscripts in the future.</p>
          </td>
         </tr>
         <tr>
          <!------------------------------------------------------------------------------------------------------------------------
                                Title for the additional notes section.
                                -------------------------------------------------------------------------------------------------------------------------->
          <td bgcolor="43729f" id="add_notes_title" style="color:white; font-family: Verdana, sans-serif; font-size: 20px;padding: 10px 15px 10px 15px">
           Call for Paper On COVID-19
          </td>
         </tr>
         <tr>
          <td bgcolor="d4f5ff" id="add_notes_text" style="color:#5c5c5c; font-family: Geneva, sans-serif; font-size: 16px;padding: 20px 15px 20px 15px">
           <p>Antibody Therapeutics is an official journal of the Chinese Antibody Society and published by the Oxford University Press. As a peer-reviewed and open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development and methodology of therapeutic antibodies for global scientific community.</p> <p>The current COVID-19 pandemic is an unprecedented global public health challenge. Antibody Therapeutics invites papers that contribute knowledge to develop therapeutics and diagnostics strategies for our battle against COVID-19. We are particularly interested in research, method or review articles regarding discovery and engineering of COVID-19 diagnostic and therapeutic antibodies for clinical applications. Given the urgency of the current global pandemic, we will provide a fast-track option for all COVID-19 manuscripts. It will take 2 weeks or less from submission to acceptance. Manuscripts should be submitted via Antibody Therapeutics online <a href="https://mc.manuscriptcentral.com/abt">submission site</a>. Authors can publish in the journal with no charge (see the <a href="https://academic.oup.com/abt/pages/General_Instructions">authors’ instructions</a>).</p> <p>Correspondence or questions: <a href="mailto:abt@oup.com">contact editorial office</a></p> <p><b>Editorial operation team</b></p> <p><b>Antibody Therapeutics, an official journal of Chinese Antibody Society</b></p>
          </td>
         </tr>
        </table>
       </td>
      </tr>
      <tr>
       <td>
        <hr/>
        <!--Horizontal Line Divider. Don't remove-->
       </td>
      </tr>
      <tr>
       <td bgcolor="white" style="padding: 30px 30px 30px 30px;">
        <table border="0" cellpadding="0" cellspacing="0" width="100%">
         <tr>
          <td style="color: #43729f; font-family: Verdana, sans-serif; font-size: 14px;" width="75%">
           <p>
            © Chinese Antibody Society 2020.
           </p>
           <p>
            Follow us on Wechat:
            <b>
             chinese_antibody
            </b>
            or
            <a href="https://chineseantibody.org/">
             visit website
            </a>
           </p>
          </td>
          <td align="right" width="25%">
           <table border="0" cellpadding="0" cellspacing="0">
            <tr>
             <td style="font-family: Verdana, sans-serif; font-size: 12px; font-weight: bold;">
              <img alt="Wechat" border="0" height="38" src="https://res.cloudinary.com/dwawcx2hl/image/upload/v1589466031/Logo/wechat_m1vetn.png" style="display: block;" width="38"/>
             </td>
             <!--spacer between logos-->
             <td style="font-size: 0; line-height: 0;" width="20">
             </td>
             <td style="font-family: Verdana, sans-serif; font-size: 12px; font-weight: bold;">
              <a href="https://twitter.com/ChineseAntibody" style="color: #ffffff;">
               <img alt="Twitter" border="0" height="38" src="https://res.cloudinary.com/dwawcx2hl/image/upload/v1589466031/Logo/twitter_pooabc.png" style="display: block;" width="38"/>
              </a>
             </td>
             <!--spacer between logos-->
             <td style="font-size: 0; line-height: 0;" width="20">
             </td>
             <td style="font-family: Verdana, sans-serif; font-size: 12px; font-weight: bold;">
              <a href="https://www.linkedin.com/company/chineseantibodysociety/" style="color: #ffffff;">
               <img alt="Linkedin" border="0" height="38" src="https://res.cloudinary.com/dwawcx2hl/image/upload/v1589466031/Logo/linkedin_wtjojb.png" style="display: block;" width="38"/>
              </a>
             </td>
            </tr>
           </table>
          </td>
         </tr>
        </table>
       </td>
      </tr>
     </table>
    </td>
   </tr>
  </table>
 </body>
</html>